Chief Scientific Officer, Polyphor
Balixafortide: Phase III CXCR4 Inhibitor for Cancer
Daniel Obrecht, Ph. D., is co-founder and Chief Scientific Officer of Polyphor Ltd. He spent 11 years at the Central Research Laboratories of Roche Basle. In his final position he was Head of the Combinatorial Chemistry Group.